TFFP - NetworkNewsBreaks - TFF Pharmaceuticals Inc. (NASDAQ: TFFP) Featured in ROTH Equity Research Report
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “TFFP utilizes its proprietary Thin Film Freezing (TFF) technology to develop improved versions of existing therapeutics through formulating them as dry powders that can be inhaled directly or reconstituted for injection. Lead products TFF Vori and TFF Tac are improved versions of voriconazole and tacrolimus, differentiated by TFF to have a vastly improved solubility, and likely higher efficacy and lower toxicity due to their delivery straight to the lung for invasive pulmonary aspergillosis (IPA) and preventing lung transplant rejection, respectively.”
To request access to the full report, visit http://nnw.fm/DXCr3
About TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.